• Molecular NameAlosetron
  • SynonymAlosetron HCl
  • Weight294.358
  • Drugbank_IDDB00969
  • ACS_NO122852-42-0
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.5
  • pkaN/A
  • LogD (pH=7, predicted)2.24
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.63
  • LogSw (predicted, AB/LogsW2.0)0.03
  • Sw (mg/ml) (predicted, ACD/Labs)0.35
  • No.of HBond Donors1
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds2
  • TPSA53.92
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA 5-HT3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in women only.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability60.0
  • Protein binding82.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (including CYP2C9, CYP3A4 and CYP1A2)
  • Half life1.5~1.7 h
  • ExcretionRenal 73%, faecal 24%
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityAdverse effects reported in more than 1% of IBS patients and more frequently than in placebo group include constipation, gastrointestinal, abdominal dyscomfort and pain, nausea, regurgitation and reflux, and hemorrhoids.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A